Treating acute infections with corona by...?

A clinical trial, the results of which were published, on Wednesday, in a specialized medical journal, showed that the drug “tofacitinib” for the treatment of arthritis showed promising results in the treatment of patients with severe symptoms of Covid-19 disease.

And the clinical trial, the results of which were published in the “New England Journal of Medicine,” took place on 289 people who were being treated in hospitals in 15 different locations in Brazil due to severe symptoms of Covid-19.

Half of these patients were given tofacitinib (two 10 mg tablets daily) in combination with conventional healthcare and the other half were given a placebo with the same healthcare.

After 28 days, 18% of the group that received the drug had either developed respiratory failure (eg requiring intubation or access to a respirator) or died, compared to 29% of the placebo group.

In all, 5.5% of the placebo patients died, compared to 2.8% in the tofacitinib group.

Tofacitinib is marketed under various brands, including Zeljans, which is owned by the American pharmaceutical group Pfizer.

“We are encouraged by the initial results of our randomized trial of tofacitinib in patients hospitalized with pneumonia caused by Covid-19,” said Otavio Berwanger, a physician at the Albert Einstein Hospital in Israel who conducted the clinical trial in partnership with Pfizer.

Tofacitinib is approved for use in the United States to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Other topics: 

How do you deal with someone who intelligently ignores you?

http://عشرة عادات خاطئة تؤدي إلى تساقط الشعر ابتعدي عنها